Welcome to our dedicated page for Voyager Therapeutics SEC filings (Ticker: VYGR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Voyager Therapeutics, Inc. filings document regulatory disclosures for a Nasdaq-listed biotechnology company developing neurotherapeutics for central nervous system diseases. Its Form 8-K reports include quarterly and annual financial results, corporate updates, Regulation FD investor presentations, executive officer transitions and related exhibits covering pipeline and platform information.
Proxy materials describe annual meeting matters such as director elections, advisory executive compensation votes, auditor ratification, charter matters and proposals involving authorized capital. The filing record also identifies Voyager’s common stock, par value and Nasdaq Global Select Market listing, and formalizes governance and capitalization disclosures relevant to its public-company status.
Armistice Capital, LLC and Steven Boyd report collective beneficial ownership of 4,800,000 shares of Voyager Therapeutics, Inc. common stock, representing 8.65% of the outstanding shares based on 55,468,806 shares outstanding. The filing states Armistice Capital is the investment manager of the direct holder, Armistice Capital Master Fund Ltd., and that Armistice exercises shared voting and dispositive power over the reported shares. Neither Armistice nor Mr. Boyd claim sole voting or dispositive power. The Master Fund is identified as the holder with the right to receive proceeds or dividends.